Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents

Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents

US Patent 6987103 · Granted Jan 17, 2006

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Harringtonines salts in the crystalline state and their use for the purification2018
Harringtonines salts in the crystalline state and their use for the purification2018
Cephalotaxane derivatives and their processes of preparation and purification2014
Cephalotaxane derivatives and their processes of preparation and purification2014
Nuclear fuel assembly bottom nozzle2014
Cephalotaxane derivatives and their processes of preparation and purification2010
Cephalotaxane derivatives and their processes of preparation and purification2010
Intermediates for the hemisynthesis of taxanes and preparation processes therefo2008
Cephalotaxanes, their method of preparation and their use in treatment of cancer2007
Intermediates for the hemisynthesis of taxanes and preparation processes therefo2007
Intermediates for the hemisynthesis of taxanes and preparation processes therefo2007
Cephalotaxane derivatives and their processes of preparation and purification2007